Peptide Initiative
Back to Setmelanotide

Clinical trials

Every registered trial of Setmelanotide

29 studies, 3 still enrolling.

Plain-Language Summary

Plain-language reading of the public trial registries.

In short

  • Setmelanotide has a real but limited body of human research.
  • 29 registered studies in total.
  • 3 are still enrolling people, so this is active research, not just history.

What kind of research

  • 28 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
  • About 1,933 people took part in those.

A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.

Filter

Showing 29 of 29 trials for Setmelanotide.

  • NCT07496463 Phase 2Enrolling By Invitation1 enrolled2026

    Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)

    Massachusetts General Hospital

    Pseudohypoparathyroidism Type 1a · Obesity

  • NCT06760546 Phase 3Recruiting39 enrolled2025

    A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

    Rhythm Pharmaceuticals, Inc.

    Hypothalamic Obesity · Multiple Pituitary Hormone Deficiency Genetic Form · Septo-Optic Dysplasia · Optic Nerve Hypoplasia

  • 2024-516753-45-00 Ongoing5 enrolled2025

    SETmelanotide to improve hypothalamic function in the ROHHAD-syndrome; a proof of concept study in a small mono-center cohort: the ROH-SET Study

    Universitair Medisch Centrum Utrecht

    ROHHAD syndrome

  • NCT06772597 Phase 2Active Not Recruiting18 enrolled2025

    A Study of Setmelanotide in Patients With Prader-Willi Syndrome

    Rhythm Pharmaceuticals, Inc.

    Prader-Willi Syndrome · Obesity · Hyperphagia

  • NCT06596135 Phase 3Completed28 enrolled2024

    Open-Label Extension Study of Setmelanotide

    Rhythm Pharmaceuticals, Inc.

    Obesity Associated With Defects in Leptin-melanocortin Pathway

  • NCT05812183 Phase 4Withdrawn2023

    Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity

    University of California, Los Angeles

    Dyspnea · Quality of Life

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT05774756 Phase 3Active Not Recruiting143 enrolled2023

    A Trial of Setmelanotide in Acquired Hypothalamic Obesity

    Rhythm Pharmaceuticals, Inc.

    Hypothalamic Obesity

  • NCT07674290 Phase 4Recruiting200 enrolled2023

    Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity

    Tom Hühne

    Bardet Biedl Syndrome (BBS) · Bardet Biedl Syndrome · Bardet-Biedl Syndrome (BBS) · Alstrom Syndrome

  • 2023-507634-24-00 Revoked85 enrolled2022

    RM-493-035

    Rhythm Pharmaceuticals Inc.

    Improper function of certain messenger materials in the body that control body weight and hunger in people

  • NCT04966741 Phase 3Completed12 enrolled2022

    Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

    Rhythm Pharmaceuticals, Inc.

    Bardet-Biedl Syndrome · POMC Deficiency Obesity · PCSK1 Deficiency Obesity · LEPR Deficiency Obesity

  • NCT05194124 Phase 3Completed19 enrolled2021

    Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

    Rhythm Pharmaceuticals, Inc.

    Bardet-Biedl Syndrome · POMC Deficiency

  • NCT05093634 Phase 3Completed296 enrolled2021

    EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

    Rhythm Pharmaceuticals, Inc.

    Obesity · Genetic Obesity

  • NCT04963231 Phase 2Completed164 enrolled2021

    DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

    Rhythm Pharmaceuticals, Inc.

    Genetic Obesity

  • NCT05046132 Phase 4Completed77 enrolled2021

    Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants

    Rhythm Pharmaceuticals, Inc.

    Healthy

  • NCT04725240 Phase 2Completed18 enrolled2021

    Open-Label Study of Setmelanotide in Hypothalamic Obesity

    Rhythm Pharmaceuticals, Inc.

    Hypothalamic Obesity

  • NCT04348175 Phase 1Completed32 enrolled2020

    A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment

    Rhythm Pharmaceuticals, Inc.

    Renal Insufficiency

  • NCT03746522 Phase 3Completed52 enrolled2018

    Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

    Rhythm Pharmaceuticals, Inc.

    Bardet Biedl Syndrome (BBS) · Alström Syndrome (AS)

  • NCT03651765 Phase 2/3Completed205 enrolled2018

    Long Term Extension Trial of Setmelanotide

    Rhythm Pharmaceuticals, Inc.

    Obesity Associated With Defects in Leptin-melanocortin Pathway

  • NCT03287960 Phase 3Completed15 enrolled2018

    Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity

    Rhythm Pharmaceuticals, Inc.

    Leptin Receptor Deficiency Obesity

  • NCT03262610 Phase 2Completed1 enrolled2017

    Setmelanotide in a Single Patient With Partial Lipodystrophy

    Rhythm Pharmaceuticals, Inc.

    Hypertriglyceridemia · Obesity

  • NCT02896192 Phase 3Completed15 enrolled2017

    Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity

    Rhythm Pharmaceuticals, Inc.

    Pro-opiomelanocortin (POMC) Deficiency Obesity

  • NCT03013543 Phase 2Completed213 enrolled2017

    Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

    Rhythm Pharmaceuticals, Inc.

    Genetic Obesity · Obesity · Obesity Due to Melanocortin 4 Receptor Deficiency

  • NCT02311673 Phase 2Completed40 enrolled2015

    Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

    Rhythm Pharmaceuticals, Inc.

    Prader-Willi Syndrome

  • NCT02507492 Phase 2Unknown10 enrolled2015

    RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients

    Charite University, Berlin, Germany

    Homozygous or Compound Heterozygous POMC, LEPR or PCSK1 Gene Mutation

  • NCT02041195 Phase 1/2Completed99 enrolled2014

    Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients

    Rhythm Pharmaceuticals, Inc.

    Overweight and Obesity

  • NCT01867437 Phase 1Completed15 enrolled2013

    Effects of RM-493 on Energy Expenditure in Obese Individuals

    Rhythm Pharmaceuticals, Inc.

    Obesity · Morbid Obesity

  • NCT01749137 Phase 2Completed74 enrolled2013

    Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants

    Rhythm Pharmaceuticals, Inc.

    Overweight

  • NCT02431442 Phase 1Completed57 enrolled2012

    Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers

    Rhythm Pharmaceuticals, Inc.

    Overweight · Obese

  • NCT05183802 Approved For Marketing

    An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)

    Rhythm Pharmaceuticals, Inc.

    Bardet-Biedl Syndrome (BBS) · Obesity

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Setmelanotide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.